Tag: Alnylam and Genzyme alliance

December 18, 2017 Off

Sanofi and Alnylam apply to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

Sanofi Genzyme, the specialty care global business unit of Sanofi, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the RNAi therapeutics company,…

October 2, 2015 Off

Sanofi: Genzyme Opts into Alnylam’s ALN-AT3 Hemophilia Program

By Dino Mustafić

Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.